Trial Information
Open-Label, Multicenter, Dose-Escalation Study in Subjects w/Advanced Colorectal Cancer to Evaluate the Safety, Efficacy, and Pharmacokinetics of Tarceva in Combination w/5-Fluorouracil, Leucovorin, and Irinotecan and of Bevacizumab in Combination w/Tarceva, 5-Fluorouracil, Leucovorin, and Irinotecan
Inclusion Criteria
Subjects must fulfill all of the following criteria to be eligible for study entry:
- Signed informed consent
- At least 18 years of age
- Histologically confirmed metastatic colorectal adenocarcinoma of the colon or rectum
Resected or biopsied primary tumors or metastatic site will serve as the basis for
histologic confirmation.
- Measurable disease (defined as at least one dimension >2 cm [>1 cm on spiral CT
scans])
- ECOG performance status of 0 or 1
- Life expectancy >3 months
- Use of an effective means of contraception in men and in women of childbearing
potential
- Ability to comply with study and follow-up procedures
Type of Study:
Interventional
Study Design:
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment
Authority:
United States: Food and Drug Administration
Study ID:
OSI2520g
NCT ID:
NCT00047762
Start Date:
October 2002
Completion Date:
Related Keywords:
- Colorectal Cancer
- Colorectal Neoplasms
Name | Location |
Johns Hopkins Oncology Center |
Baltimore, Maryland 21287 |
Mary Crowley Medical Research Center |
Dallas, Texas 75246 |
Indiana University Cancer Pavilion |
Indianapolis, Indiana 46202 |